RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive

Trial Details

NCT ID

NCT07413939

Phase

PHASE2 / PHASE3

Sponsor

Hoffmann-La Roche

Status

RECRUITING

Cancer Type

HER2 Positive Breast Cancer

Interventions

• RO7771950
• Tucatinib
• Trastuzumab
• Capecitabine

Locations (sample)

• Rosario, Argentina|-32.94682,-60.63932
• Clayton, Victoria, Australia|-37.91667,145.11667
• Geelong, Victoria, Australia|-38.14711,144.36069
• Melbourne, Victoria, Australia|-37.814,144.96332
• Salzburg, Austria|47.79941,13.04399

Key Eligibility Criteria

• Pathologically documented locally advanced inoperable (LAI) or metastatic breast cancer (MBC) with confirmed HER2-positive status by central labora…
• Measurable disease as per by RECIST v1.1 in stage 1. Non-measurable disease allowed in stage 2.
• Previously treated (stable or progressive) or previously untreated CNS metastases, or leptomeningeal metastases.
• At least one prior line of anti-HER2-based therapy for LAI or metastatic disease.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.